How Almac’s Trust Ownership Enables CDMO Success - interview with Franciane Chevot
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
How Almac’s Trust Ownership Enables CDMO Success - interview with Franciane Chevot
-
Narrado por:
-
De:
Acerca de esta escucha
“We are privately owned by a Trust, which means all our profits are reinvested in the company. This translates to steady growth – maybe slower compared to other service providers, but we’re quite proud of that steady growth,” explains Franciane Chevot, Senior Business Development Manager at Almac.
With 55 years of industry experience, approximately 7,500 employees, and 18 facilities worldwide across Europe, North America, and Asia, Almac has established a global footprint. However, it’s their ownership structure that truly differentiates them.
This reinvestment approach has allowed Almac to take a long-term view of business development rather than focusing on short-term gains, creating stability that benefits both the company and its clients.Ahead of CDMO Live, Franciane shares how Almac’s unique ownership structure, scientific expertise, and customer-centric approach have positioned the CDMO as a trusted partner for pharmaceutical and biotech companies across the drug development lifecycle.
Read the article